Toll-like receptor 4-Myeloid differentiation primary response 88 signaling pathway (TLR4-MyD88)

The Toll-like receptor 4-Myeloid differentiation primary response 88 (TLR4-MyD88) signaling pathway is a critical component of the innate immune system responsible for detecting Gram-negative bacterial lipopolysaccharide (LPS) and various endogenous damage-associated molecular patterns (DAMPs) (Poltorak et al., 1998; Medzhitov et al., 1997). Activation occurrs when the TLR4-MD-2 receptor complex binds its ligand at the cell surface, triggering the recruitment of the adapter protein MyD88 to the receptor's cytoplasmic Toll/interleukin-1 receptor (TIR) domain. This initiates a downstream phosphorylation cascade involving Interleukin-1 receptor-associated kinases (IRAKs) and Tumor necrosis factor receptor-associated factor 6 (TRAF6), culminating in the activation of the transcription factor NF-kappaB and the production of pro-inflammatory cytokines such as TNF-alpha and IL-6 (Akira & Takeda, 2004; Kawai & Akira, 2010). Pathological dysregulation of this pathway is a major driver in the development of sepsis, chronic inflammatory disorders, and solid tumor progression, where it facilitates tumor cell survival and immune evasion (Lucas & Maes, 2013; Wang et al., 2014). Pharmacological modulation of the TLR4-MyD88 axis has been a significant area of drug development, featuring competitive antagonists like Eritoran and intracellular signaling inhibitors like Resatorvid (TAK-242), although clinical translation has faced challenges due to patient heterogeneity and the pathway's essential role in host defense (Opal et al., 2013; Rice et al., 2010).

Other names

MyD88-dependent Toll-like receptor 4 pathwayTLR4/MyD88 signaling axisToll-like receptor 4 signaling pathwayTLR4-MyD88-NF-kappaB pathway

Drugs targeting this pathway typically function by either competitively antagonizing the extracellular TLR4/MD-2 complex to prevent ligand binding (e.g., Eritoran) or by binding to the intracellular domain of TLR4 to inhibit the recruitment of the MyD88 adapter protein (e.g., Resatorvid), thereby blocking downstream NF-kappaB activation and pro-inflammatory signaling.